- Open
- 208.40
- High
- 214.00
- Low
- 196.70
- Close
- 197.87
- Change
- -12.60 (-6.01%)
- Volume
- 2,271,273
| 14 Oct 2026 | 15:00:00 | Share Incentive Plan - Director/PDMR Shareholding |
| 12 Oct 2026 | 16:00:00 | Director/PDMR Shareholding |
| 2 Oct 2026 | 07:00:03 | Holding(s) in Company |
| 1 Oct 2026 | 16:00:00 | Issue of Equity and Total Voting Rights |
| 1 May 2026 | Oxford Nanopore Technologies plc Accounts 31-12-2025 | |
| 30 Apr 2025 | Oxford Nanopore Technologies plc Accounts 31-12-2024 | |
| 7 Jun 2024 | Annual Report and Accounts 2023 |
Oxford Nanopore Technologies plc develops and commercializes a novel nanopore-based sensing platform for DNA and RNA analysis. The company offers rapid, accessible, and affordable sequencing solutions primarily for research, clinical, and biopharmaceutical applications. Its technology is utilized by researchers, healthcare providers, and industrial customers, enabling insights in areas such as infectious disease, oncology, and synthetic biology. Oxford Nanopore operates globally, focusing on expanding its presence in both research and applied markets.
| 14 Oct 2026 | 15:00:00 | Share Incentive Plan - Director/PDMR Shareholding |
| 12 Oct 2026 | 16:00:00 | Director/PDMR Shareholding |
| 2 Oct 2026 | 07:00:03 | Holding(s) in Company |
| 1 Oct 2026 | 16:00:00 | Issue of Equity and Total Voting Rights |
| 1 May 2026 | Oxford Nanopore Technologies plc Accounts 31-12-2025 | |
| 30 Apr 2025 | Oxford Nanopore Technologies plc Accounts 31-12-2024 | |
| 7 Jun 2024 | Annual Report and Accounts 2023 |
Oxford Nanopore Technologies plc develops and commercializes a novel nanopore-based sensing platform for DNA and RNA analysis. The company offers rapid, accessible, and affordable sequencing solutions primarily for research, clinical, and biopharmaceutical applications. Its technology is utilized by researchers, healthcare providers, and industrial customers, enabling insights in areas such as infectious disease, oncology, and synthetic biology. Oxford Nanopore operates globally, focusing on expanding its presence in both research and applied markets.
| 16 Sept 2026 | 07:00:05 | Preliminary injunction against MGI Tech GmbH |
| 30 Sept 2026 |
| FTSE 250 movers: Greggs, Saga surge |
| 4 Sept 2026 | FTSE 250 movers: Oxford Nanopore, Rosebank in the red |
| 4 Sept 2026 | Director dealings: Oxford Nanopore CFO raises stake |
| 1 Sept 2026 | UK stock market winners and losers: August 2026 |
| 25 Aug 2026 | Oxford Nanopore appoints David Miller as Chief Development and Product Officer |
| 24 Aug 2026 | Oxford Nanopore target price hiked to 196p by Panmure Liberum on strategic pivot |
Lord Spencer of Alresford has interests in this issuer
| 16 Sept 2026 | 07:00:05 | Preliminary injunction against MGI Tech GmbH |
| 30 Sept 2026 |
| FTSE 250 movers: Greggs, Saga surge |
| 4 Sept 2026 | FTSE 250 movers: Oxford Nanopore, Rosebank in the red |
| 4 Sept 2026 | Director dealings: Oxford Nanopore CFO raises stake |
| 1 Sept 2026 | UK stock market winners and losers: August 2026 |
| 25 Aug 2026 | Oxford Nanopore appoints David Miller as Chief Development and Product Officer |
| 24 Aug 2026 | Oxford Nanopore target price hiked to 196p by Panmure Liberum on strategic pivot |
Lord Spencer of Alresford has interests in this issuer
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £80.13bn | +0.1% | |
ONTOxford Nanopore Technologies plc | £1.94bn | +0.5% |
| £173m | +0.2% | |
| £105m | -0.1% | |
| £44m | -0.4% | |
| £15m | -0.6% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £80.13bn | +0.1% | |
ONTOxford Nanopore Technologies plc | £1.94bn | +0.5% |
| £173m | +0.2% | |
| £105m | -0.1% | |
| £44m | -0.4% | |
| £15m | -0.6% |
